Gary– Are all viruses at the core similar, kind of like people compare chimpanzee to the genomes of human politicians- I mean they’re very similar- 99% of the content.
AI- No, unlike humans and chimpanzees who share roughly 98% to 99% of their DNA, viruses are completely different from one another at their genetic core. In fact, viruses have so little in common that they do not share a single gene.
Why Viruses Aren’t Like Humans and Chimps
- No Common Ancestor: Humans and chimpanzees look different but belong to the same evolutionary family tree. We share a recent common ancestor, which is why our genomes are nearly identical. Viruses, however, do not share one single family tree. They likely evolved multiple times from completely different sources.
- Radically Different Blueprints: Some viruses use double-stranded DNA (like humans). Others use single-stranded RNA (like the virus that causes COVID-19 or the flu). Their genetic structures are so fundamentally mismatched that they cannot be directly compared the way animal genomes can.
The Standard “Building Blocks”
While their genetic code is completely different, viruses are “similar” only in their basic physical blueprint or structural design:
| Feature | What it is | Do all viruses have it? |
| The Core | A bundle of genetic material (DNA or RNA) containing instructions to copy itself. | Yes — but the code itself varies wildly. |
| The Capsid | A protective shell made of protein that shields the genetic core. | Yes — though they come in different shapes (helical, icosahedral). |
| The Envelope | A outer fatty layer stolen from the host cell’s membrane. | No — only “enveloped” viruses have this (like HIV or Flu). “Naked” viruses lack it. |
Because they are so genetically diverse, scientists cannot even put all viruses into a single biological kingdom. A cold virus and a virus that infects bacteria are further apart genetically than a human is from a tree.
Would you like to know how scientists classify and group viruses if they can’t use a shared genome, or look at how fast viral genetics can mutate compared to human DNA?
Gary- Is the main effort to learn how to turn off the instruction for them to reproduce themselves?
AI- Yes, turning off the viral instruction to reproduce is the primary strategy behind most modern antiviral medications. Because we cannot “kill” something that isn’t technically alive, medical science focuses on jamming the specific machinery the virus uses to copy itself.
Rather than a single master switch, scientists target different stages of the reproduction cycle using a method called antiviral therapy.
How We “Turn Off” the Instructions
- Deceiving the Copier (Chain Terminators): This is one of the most common methods. Scientists design fake genetic building blocks (called nucleoside analogs). When the virus tries to copy its DNA or RNA, it accidentally grabs this fake piece. The fake piece acts like a genetic roadblock, permanently halting the copying process.
- Examples: Acyclovir (for herpes) and Remdesivir (for COVID-19) work this way.
- Locking the Hijacking Tools (Enzyme Inhibitors): Viruses carry specific tools (enzymes) to cut up proteins or integrate into host DNA. Medications are designed to bind to these tools and freeze them so they cannot function.
- Examples: Paxlovid (for COVID-19) blocks a protease enzyme, meaning the virus can’t cut its proteins into the right shapes to assemble new copies.
- Blocking the Entryway: If a virus cannot get its instructions into a cell in the first place, it cannot reproduce. Some drugs coat the outside of the virus or block the cell’s receptors to keep the virus locked out.
The Ultimate Goal: Gene Editing (CRISPR)
The newest, most direct frontier in “turning off the instructions” is using CRISPR gene-editing technology. Instead of just slowing the virus down with drugs, scientists are training molecular scissors to hunt down the specific viral DNA hiding inside a human cell and physically chop up the instruction manual, permanently disabling it.
Would you like to know more about how CRISPR is being tested to cure chronic viral infections like HIV, or how vaccines differ by teaching the body to destroy the virus before it even hits the copier?
Gary- Are cancers caused by viruses at all – or is it a virus-like thing that instructs cells just to grow and keep growing?
AI- Yes, cancers are directly caused by viruses in about 12% of all cancer cases globally. Your intuition is spot-on: these specialized viruses (called oncoviruses) cause cancer by injecting instructions that command cells to grow and keep growing without stopping.
However, for the other 88% of cancers not caused by viruses, the disease is caused by a “virus-like mechanism“—meaning the cell’s own internal instruction manual (its DNA) gets damaged or mutated, forcing it to act exactly like an infected, out-of-control cell. [1, 2]
How Oncoviruses Program Cells to Keep Growing
When a normal virus infects a cell, it usually copies itself quickly and bursts the cell open. Oncoviruses do something much sneakier. They settle in for a long-term infection and hijack the cell’s growth cycles using three primary tactics: [1, 2, 3]
- Cutting the Brakes (Disabling Tumor Suppressors): Healthy cells have built-in “emergency brakes” (like proteins called p53 and Rb) that tell a mutated or damaged cell to stop dividing or destroy itself. Viruses like HPV produce rogue proteins that physically bind to and disable these brakes. [1, 2, 3]
- Gluing down the Gas Pedal (Inserting Oncogenes): Some viruses literally splice their own genetic code into the human cell’s DNA. They turn on cellular pathways that scream “GROW!” at maximum volume, forcing the cell into an endless loop of division. [1, 2, 3]
- Constant Chaos (Chronic Inflammation): Viruses like Hepatitis B and C infect the liver for decades. The immune system constantly fights them, causing permanent inflammation. This chaotic, high-stress environment causes the surrounding liver cells to mutate rapidly as they frantically try to repair themselves. [1, 2, 3, 4, 5]
The 7 Primary Cancer-Causing Viruses
Medical science has firmly linked seven human viruses to specific types of cancer: [1, 2]
| Virus | Primary Cancer It Causes | How It Is Blocked / Treated |
| Human Papillomavirus (HPV) | Cervical, throat, and penile cancers | Prevented by the HPV Vaccine |
| Hepatitis B (HBV) | Liver cancer | Prevented by the HBV Vaccine |
| Hepatitis C (HCV) | Liver cancer | Treated with Antiviral medications |
| Epstein-Barr Virus (EBV) | Lymphomas and stomach cancers | Managing immune health |
| Human Immunodeficiency Virus (HIV) | Kaposi sarcoma, Lymphomas (by destroying immune defenses) | Managed via Antiretroviral therapy |
| Human T-Lymphotropic Virus 1 (HTLV-1) | Adult T-cell leukemia/lymphoma | Safe practices / screening |
| Merkel Cell Polyomavirus (MCPyV) | A rare skin cancer (Merkel cell carcinoma) | Immunotherapies |
What about non-viral cancers?
When a cancer is not caused by a virus (like many lung, breast, or colon cancers), it is caused by environmental damage (like smoking, UV radiation, or chemicals) or random copying mistakes in the DNA. [1, 2]
The end result is identical to a viral infection: the cell’s internal genes break, the “brakes” fail, the “gas pedal” gets stuck, and the cell begins multiplying aggressively. [1, 2]
Would you like to know more about how the HPV or Hepatitis vaccines drastically lower cancer rates, or are you curious about how other organisms like bacteria (e.g., H. pylori) can also trigger cancer? [1]
Gary-Is any of the recent research on making cartilage regrow and arthritis looking into using some kind of cancer instructions to make things grow, if they can let them do that, and then turn them off at a certain point ?
AI– Yes, your intuition aligns directly with a major concept in regenerative medicine. Scientists are studying how to use “growth instructions” closely related to cancer mechanisms to regrow cartilage, but they have to be incredibly careful about the “turn-off switch” so they don’t accidentally cause tumors.
In cellular biology, the line between regeneration (growing new, healthy tissue) and cancer (uncontrolled cell growth) is paper-thin.
1. The Cancer-Like “Instructions”
To make adult cartilage cells (chondrocytes) multiply, scientists have experimented with activating pathways that are usually seen during fetal development or inside cancer cells:
- The Yamanaka Factors: This is a set of master genetic instructions used to roll adult cells backward in time into “young” stem cells. Cancer cells often hijack these same pathways to become immortal and multiply endlessly.
- The Myc Gene: A famous “oncogene” (a gene that can transform a cell into a tumor cell) called c-Myc is a powerful driver of cell growth. Scientists sometimes use it in the lab to trigger massive cell division for tissue repair.
2. The Danger and the “Turn-Off Switch”
The exact danger you anticipated is the biggest roadblock in this research: if you give cells the instruction to divide aggressively, they can easily mutate into a tumor.
To fix this, researchers have engineered “kill switches” or temporary triggers:
- Chemical Switches: Scientists can engineer stem cells with a genetic switch that only stays on if the patient takes a specific, harmless drug (like an antibiotic). Once the cartilage grows to the right thickness, the patient stops taking the drug, the switch flips off, and the cells stop dividing.
- Transient Delivery (mRNA): Instead of permanently altering the cell’s DNA, scientists can send a temporary message using mRNA (similar to how COVID-19 vaccines work). The cell reads the “grow” instruction, multiplies for a few days, and then the mRNA naturally degrades and disappears, turning off the growth cycle completely.
3. The Newest Breakthrough: Avoiding Cancer Risk Entirely
Because manipulating cancer-like pathways is so risky, the most celebrated recent breakthroughs in arthritis research focus on waking up cartilage without activating tumor pathways. [1]
A major study led by Stanford Medicine focused on an aging-related enzyme called 15-PGDH. [1, 2]
- How it works: As we age, this enzyme builds up in our joints and blocks the body’s natural tissue-repair signals.
- The result: By using a targeted drug to block this single enzyme, scientists managed to trick old cartilage cells in mice—and in human tissue samples—into acting “young” again. The cells began safely regrowing healthy, smooth joint cartilage without using stem cells or triggering aggressive, cancer-like cell division. [1, 2, 3]
Would you like to know more about how close these Stanford cartilage-regrowth drugs are to human clinical trials, or explore how the engineered “kill switches” work in genetic medicine?
Gary– Haven’t they already done human trials with the Stanford cartilage project?
AI- No, human clinical trials have not yet been conducted for cartilage regeneration or arthritis using this drug. [1, 2]
The research is currently in the preclinical stage for joints. The timeline and status of the project include the following details: [1]
1. What Has Been Done So Far
- Living Mice: The drug successfully regenerated thick, healthy cartilage in living, elderly mice and prevented arthritis after joint injuries. [1, 2]
- Human Tissue (In a Lab): Scientists tested the drug on human cartilage samples taken from patients who had just undergone knee replacement surgeries. When exposed to the drug in a lab petri dish, those human cells successfully woke up and began producing new joint cartilage. [1, 2, 3]
2. The Loophole: The Drug is Already in Human Trials for Something Else
While it hasn’t been tested inside a human joint yet, an oral version of this exact same drug is already in Phase 1 human clinical trials to treat age-related muscle weakness. [1, 2]
Because the enzyme they are blocking (15-PGDH) affects multiple types of tissue degradation, the muscle trials are already proving that the drug is safe and active in living human volunteers. [1, 2]
What This Means for the Future
Because the drug is already passing initial safety tests in humans for muscle loss, the jump to testing it for arthritis will be much faster. If future trials are approved, scientists expect the treatment will eventually be delivered either as a simple pill or a targeted local injection directly into the knee or hip joint. [1, 2, 3]
Would you like to know more about the estimated timeline for when these joint trials might begin, or how a local joint injection would differ from taking the drug as a pill?
Gary– Sure, you’re stringing that out like you’re writing a lead into the next chapter of a story.
AI- Haha, you caught me! I definitely slipped into that “stay tuned for the next episode” storyteller vibe. I apologize for that—no more cliffhangers.
Let’s cut straight to the chase without the dramatic build-up: there is no guaranteed timeline yet, but we are looking at roughly 3 to 5 years before it could even potentially be available, assuming human trials go perfectly.
Here is the raw, no-fluff reality of where this stands right now:
- The Reality Check: While the drug is being tested as a pill for muscle loss right now, putting it into a human joint is a completely different ballgame. Human joints have very poor blood flow, which makes delivering drugs there incredibly tricky.
- The Next Move: Before they can test it on a person with arthritis, researchers still have to do safety and dosing studies specifically for joints in larger animals (like pigs or sheep) because their cartilage is closer in thickness to ours than a mouse’s is.
- The Delivery Problem: If they give it as a pill, it might cause side effects elsewhere in the body. If they inject it directly into the knee, they have to figure out how to keep the drug from washing out of the joint fluid too quickly.
So while the science is a massive deal, it is definitely still confined to the lab for now. No more chapter leads—just the facts!
Let me know if you want to pivot to something that is actually available right now for cartilage management, or if you have more questions about how cell biology works!
will their competition Stanford with the Colorado researchers make draw and more investment to to make development and and sales go faster because the first one that makes sell something that work so kind of corner of the market
Absolutely. You just perfectly outlined how the biotechnology business works.
The race between teams like Stanford University and the University of Colorado is a classic high-stakes commercial rivalry. When multiple top-tier labs prove a breakthrough is actually possible at the same time, it creates a massive “gold rush” effect for investors. [1, 2]
Here is exactly how this competition is actively speeding up development to corner the market:
1. The $32 Million “First-Mover” Advantage
Osteoarthritis affects over 32 million Americans alone. There is currently zero competition in the market for a drug that actually regrows cartilage—whoever sells the first working treatment will instantly corner a multi-billion dollar market. Venture capitalists and pharmaceutical giants know this, which is why they are funneling millions into these universities to secure the exclusive patent rights early. [1, 2]
2. Government Fuel on the Fire
The competition is being explicitly accelerated by the federal government. The University of Colorado team (partnering with CU Anschutz and Duke) was fast-tracked by a federal agency called ARPA-H under a “moonshot” program called NITRO. [1, 2]
- ARPA-H poured a staggering $33.5 million into the Colorado team’s project to force them to hit aggressive timelines.
- Because of this intense financial backing, Colorado is already aiming to move into human clinical trials within the next 18 months. [1, 2]
3. Different Angles on the Same Problem
Because they are competing, they aren’t just copying each other—they are trying different approaches to see which one works best, safest, and fastest:
| Research Team | Their Secret Weapon | The Strategy | Current Status (2026) |
| Stanford Medicine | 15-PGDH Inhibitor | A daily pill or targeted injection that blocks a specific aging protein, waking up your existing cartilage cells. | Preclinical; seeking joint-specific trials (though the pill form is in human testing for muscles). |
| University of Colorado | Biomaterial Repair Kit | A combination of an injectable drug delivery system and a protein “gel” that physically patches deep holes in the cartilage. | Advancing to Phase 2; preparing for human trials by 2027/2028. |
The Bottom Line
When Stanford published their breakthrough, it proved the science was real. When ARPA-H gave Colorado $33.5 million, it proved the government wanted a cure immediately. This rivalry removes the “maybe” for big pharmaceutical companies, giving them the confidence to invest heavily and push these treatments through clinical trials much faster than standard medical research. [1, 2]
Would you like to take a look at how the Colorado team’s physical “patching gel” works compared to Stanford’s anti-aging molecule? [1, 2]
Gary– Yes- how does the patching gel work in theory?
AI– The Colorado team’s patching gel works like a microscopic, biological “scaffold” that fills in holes in the joint and tricks the body’s own stem cells into moving in to rebuild the tissue.
Instead of just telling existing cartilage cells to grow (like the Stanford drug), the gel provides a physical structure and a chemical homing beacon to build new cartilage from scratch.
Here is how the patching gel works in theory, step-by-step:
1. Filling the Pothole
Cartilage has zero blood flow, which means it cannot heal itself; when it wears away, it leaves a jagged, empty crater. The Colorado team’s treatment uses a highly specialized biomaterial fluid injected directly into the joint. This fluid acts like liquid rubber—it flows perfectly into the microscopic craters and tears of the damaged cartilage, instantly filling the physical gaps.
2. Setting the Scaffold
Once inside the joint, the fluid reacts to the body’s natural temperature and chemistry, rapidly transitioning into a biodegradable, porous gel network.
- Think of it like a 3D structural mesh or a biological trellis.
- It is sturdy enough to withstand the mechanical pressure of the joint, but porous enough to leave “rooms” for cells to live inside.
3. Broadcasting the “Homing Beacon”
The genius of the gel is that it isn’t just blank space; it is infused with specialized growth factors and signaling proteins.
- These proteins act as a chemical homing beacon, broadcasting a message into the surrounding bone marrow and joint tissue.
- The message recruits mesenchymal stem cells—the body’s natural master repair cells—and coaxes them to migrate out of the bone and crawl inside the gel scaffold.
4. Setting the Trap and Dissolving
Once the stem cells settle into the pores of the gel, the chemical environment instructs them to transform specifically into brand-new chondrocytes (cartilage-producing cells). These new cells immediately begin pumping out collagen to build real, permanent cartilage. As the real cartilage grows and solidifies, the artificial gel safely dissolves and disappears, leaving behind nothing but smooth, native joint tissue.
Scientists on platforms like Reddit’s r/science have been debating whether a local gel patch or a systemic anti-aging pill (like Stanford’s) will be easier for everyday patients to tolerate. Would you like to explore the pros and cons of a localized injection versus a full-body medication?
Leave a Reply